Key facts
- It has raised $13.8M; the latest was Seed Round ($3.0M) in Nov 2024.
- Notable investors include Y Combinator, Endless Frontier Labs, Tiny Supercomputer Investment Company, Possible Ventures, ZAKA VC — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Sensible Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Sensible Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sensible Biotechnologies
Developer of he world's first cell-based design, optimisation and manufacturing platform to make pure, non-immunogenic, and highly functional messenger RNA (mRNA) to unlock the next generation of messenger RNA (mRNA) medicines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling the healthcare industry to provide optimal medicines to their patients and improve accessibility to next-generation treatments.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 25
- Website
- sensible.bio/
- Ownership
- Privately Held (backing)
Sensible Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sensible Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sensible Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.